Welcome to Pipeline Review

Generex Biotechnology, and their wholly owned subsidiary Antigen Express, are developing promising new drugs to treat diabetes, as well as synthetic peptide vaccines targeting HER2/neu cancer and pandemic flu. The flagship product for Generex is Oral-lyn buccal insulin. Antigen Express' leading vaccine is the AE37 HER2/neu synthetic peptide vaccine to prevent breast cancer recurrence. I am not qualified to offer investment or medical advice, and make no claims that I am an expert in these areas. I am a layman and a shareholder in this company. The left side of Pipeline Review holds blogs regarding Generex and Antigen Express, while the right side offers items of due diligence mixed with my analysis which may be of interest to others seeking to learn about Generex's pipeline. If the left side only shows the latest blog, click on the word home to view them all.

Search This Blog

Friday, September 23, 2011

New AE37 Phase II Data to be Presented at SABCS 2011

Researchers from the United States Military Cancer Institute will present new study findings from the ongoing Phase II trial of AE37 as a preventative cancer vaccine at the upcoming San Antonio Breast Cancer Symposium. The SABCS is a collaboration between the Cancer Therapy & Research Center (CTRC) at UT Health Science Center San Antonio and the American Association for Cancer Research (AACR). The symposium is the premier event for presenting and discussing the latest in breast cancer research.

The SABCS takes place between December 6th and 10th, and is held at the Henry B. Gonzalez Convention Center, San Antonio, Texas. The abstract and poster relating to AE37 will be shown during Poster Session 1, "Treatment - Therapeutic Strategies: Immunotherapy". The following is the title with listed authors from the USMCI:

P1-13-01 An Update of a Phase II Trial of the HER2 Peptide AE37 Vaccine in Breast Cancer Patients To Prevent Recurrence
Hale DF, Perez S, Sears AK, Clifton GT, Vreeland TJ, Holmes JP, Ardavanis A, Pistamaltzian N, Rellias G, Ponniah S, Papamichail M, Peoples GE, Mittendorf EA. Brooke Army Medical Center, Ft. Sam Houston, TX; Saint Savas Cancer Hospital, Athens, Greece; Naval Medical Center San Diego, San Diego, CA; Uniformed Services University of the Health Sciences, USMCI, Bethesda, MD; UT M.D. Anderson Cancer Center, Houston, TX.

The full abstract will be available during the event. Click on the title of the AE37 abstract to view the SABCS website.